Literature DB >> 27052552

Protective role of misoprostol against cisplatin-induced ototoxicity.

Murat Doğan1,2, Halil Polat3, Mehmet Yaşar3, Altan Kaya3, Ali Bayram3, Fatma Şenel4, İbrahim Özcan3.   

Abstract

Cis-diammineedichloroplatinum (cisplatin) is a chemotherapeutic agent that is widely used in the treatment of many cancers. Nephrotoxicity, ototoxicity and neurotoxicity are dose-limiting adverse effects for cisplatin. The cellular and molecular mechanisms underlying cisplatin-induced ototoxicity aren't fully understood. It has been proposed that cisplatin primarily cause damage at the cochlea, outer hair cells in particular, leading to excessive production of free oxygen radicals in the organ of Corti, stria vascularis, spiral ligament, and spiral ganglionic cells. The cytotoxicity is associated with the generation of reactive oxygen species (ROS); thus, there is an increasing interest on antioxidants with an effort to discover the established protection against cisplatin-induced ototoxicity over time. Misoprostol (MP) has gained considerable interest as a reactive oxygen species scavenger in recent years. To best of our knowledge, there is no study about protective effect of MP, a prostaglandin E1 (PGE1) analogue, on cisplatin-induced ototoxicity. In our study, we show that protective effects of misoprostol on cisplatin-induced ototoxcity on rats.

Entities:  

Keywords:  Cisplatin; Misoprostol; Otoacoustic emission; Ototoxcity; Rat

Mesh:

Substances:

Year:  2016        PMID: 27052552     DOI: 10.1007/s00405-016-4031-4

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  41 in total

1.  Reduction of cisplatin ototoxicity in rats by oral administration of pomegranate extract.

Authors:  Zahide Mine Yazici; Aysenur Meric; Ahmet Midi; Yasar Volkan Arınc; Volkan Kahya; Gunter Hafız
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-27       Impact factor: 2.503

2.  Protective effect of thymoquinone against cisplatin-induced ototoxicity.

Authors:  Mustafa Sagit; Ferhat Korkmaz; Alper Akcadag; Mehmet Akıf Somdas
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-17       Impact factor: 2.503

3.  Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity.

Authors:  Hyung-Jin Kim; Jeong-Han Lee; Se-Jin Kim; Gi Su Oh; Hae-Dalma Moon; Kang-Beom Kwon; Channy Park; Byung Hyun Park; Ho-Kyun Lee; Sang-Young Chung; Raekil Park; Hong-Seob So
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

Review 4.  Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.

Authors:  Carlos Sostres; Carla J Gargallo; Maria T Arroyo; Angel Lanas
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-04       Impact factor: 3.043

5.  Synthetic prostaglandin E1 misoprostol as a treatment for tinnitus.

Authors:  W Briner; J House; M O'Leary
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1993-06

6.  Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats.

Authors:  Xinyan Huang; Craig A Whitworth; Leonard P Rybak
Journal:  Otol Neurotol       Date:  2007-09       Impact factor: 2.311

Review 7.  Cisplatin ototoxicity and protection: clinical and experimental studies.

Authors:  Leonard P Rybak; Debashree Mukherjea; Sarvesh Jajoo; Vickram Ramkumar
Journal:  Tohoku J Exp Med       Date:  2009-11       Impact factor: 1.848

8.  WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.

Authors:  Michael W Church; Brian W Blakley; Don L Burgio; Anil K Gupta
Journal:  J Assoc Res Otolaryngol       Date:  2004-05-20

9.  Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate.

Authors:  H Asako; P Kubes; J Wallace; R E Wolf; D N Granger
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

10.  Possible protective effect of sertraline against cisplatin-induced ototoxicity: an experimental study.

Authors:  Murat Ozturk; Selcuk Ucar; Fatih Sarı; Selvet Erdogan; Murat Topdag; Mete Iseri
Journal:  ScientificWorldJournal       Date:  2013-10-01
View more
  2 in total

1.  GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.

Authors:  Eder C Pincinato; Ericka F D Costa; Leisa Lopes-Aguiar; Guilherme A S Nogueira; Tathiane R P Lima; Marília B Visacri; Anna P L Costa; Gustavo J Lourenço; Luciane Calonga; Fernanda V Mariano; Albina M A M Altemani; Cláudia Coutinho-Camillo; Carlos T Chone; Celso D Ramos; João M C Altemani; Patrícia Moriel; Carmen S P Lima
Journal:  Sci Rep       Date:  2019-06-27       Impact factor: 4.379

2.  Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients.

Authors:  Guilherme Augusto Silva Nogueira; Ericka Francislaine Dias Costa; Leisa Lopes-Aguiar; Tathiane Regine Penna Lima; Marília Berlofa Visacri; Eder Carvalho Pincinato; Gustavo Jacob Lourenço; Luciane Calonga; Fernanda Viviane Mariano; Albina Messias de Almeida Milani Altemani; João Maurício Carrasco Altemani; Patrícia Moriel; Carlos Takahiro Chone; Celso Dario Ramos; Carmen Silvia Passos Lima
Journal:  Oncotarget       Date:  2018-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.